Autonomix Medical, Inc. announced on July 23, 2026, the issuance of U.S. Patent No. 12,471,776, titled "ANS Assessment Systems, Kits, and Methods," strengthening its intellectual property portfolio. The patent broadly covers systems, devices, and methods for monitoring physiologic signals to assess autonomic nervous system (ANS) activity. This technology is designed to evaluate sympathetic and parasympathetic nervous system function through multiple physiologic assessment techniques.

The patented technology includes systems capable of monitoring physiologic and electrophysiological signals using advanced imaging, sensors, and algorithms. These innovations have potential applications across numerous disease states associated with autonomic dysfunction. The patent also encompasses technologies that may support patient selection, procedural guidance, treatment feedback, and post-treatment monitoring across a broad range of neuromodulation applications.

Brad Hauser, Chief Executive Officer of Autonomix, stated that the newly issued patent strengthens the company's innovation and technological foundation. He emphasized that Autonomix is building a differentiated technology platform to transform how physicians identify, target, and treat diseases involving the peripheral nervous system. The company believes this patent establishes a valuable leadership position in emerging medical technology.

Autonomix is initially developing its technology for the treatment of pain, with initial trials focused on pancreatic cancer. The platform has potential indications in cardiology, hypertension, and chronic pain management. The technology is investigational and has not yet been cleared for marketing in the United States.

Key Details of the Patent

Autonomix Medical, Inc. has entered into a warrant inducement agreement with an investor for the immediate exercise of outstanding warrants, a move expected to generate approximately $2.6 million in gross proceeds. The agreement involves the exercise of November 2025 Warrants to purchase 428,731 shares of common stock at an amended exercise price of $6.00 per share. The transaction is slated to close on or about July 15, 2026, pending customary conditions.

Transaction Details

The investor has agreed to exercise the outstanding November 2025 Warrants, which were originally issued on November 19, 2025. The resale of the shares issuable upon exercise is registered under an effective registration statement on Form S-3 (File No. 333-291825). Maxim Group LLC acted as the warrant inducement agent and financial advisor for the transaction.

New Warrants Issued

As consideration for the immediate cash exercise, Autonomix Medical agreed to issue unregistered Series D-1 and Series D-2 warrants to the investor. These new warrants allow the purchase of an aggregate of 428,731 shares each, with an exercise price of $5.75 per share. The warrants are exercisable immediately upon issuance and will expire five and a half years from the date of issuance. The company intends to file a registration statement with the Securities and Exchange Commission to cover the resale of shares issuable upon exercise of the new warrants.

Key Terms of the Agreement

The new warrants are being offered in a private placement pursuant to an exemption from the registration requirements of the Securities Act of 1933. The shares issuable upon their exercise have not been registered under the 1933 Act and may not be offered or sold in the United States absent registration or an applicable exemption.